Indication

For treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age

Medicine details

Medicine name:
ruxolitinib (Opzelura)
SMC ID:
SMC2634
Pharmaceutical company
Incyte Biosciences UK Ltd
BNF chapter
Skin
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC